Daniel F. Heitjan, Ph.D.
Daniel F. Heitjan, Ph.D.
Professor of Biostatistics in Biostatistics and Epidemiology
Department: Biostatistics and Epidemiology
Graduate Group Affiliations
Contact information
Department of Biostatistics & Epidemiology
University of Pennsylvania Perelman School of Medicine
622 Blockley Hall, 423 Guardian Drive
Philadelphia, PA 19104-6021
University of Pennsylvania Perelman School of Medicine
622 Blockley Hall, 423 Guardian Drive
Philadelphia, PA 19104-6021
Office: (215) 573-7328
Fax: (215) 573-4865
Fax: (215) 573-4865
Email:
dheitjan@mail.med.upenn.edu
dheitjan@mail.med.upenn.edu
Publications
Education:
B.Sc. (Mathematics)
University of Chicago, 1981.
(Applied Mathematics)
MIT, 1982.
M.Sc. (Statistics)
University of Chicago, 1984.
PhD (Statistics)
University of Chicago, 1985.
Permanent linkB.Sc. (Mathematics)
University of Chicago, 1981.
(Applied Mathematics)
MIT, 1982.
M.Sc. (Statistics)
University of Chicago, 1984.
PhD (Statistics)
University of Chicago, 1985.
Description of Research Expertise
BiostatisticsCancer
Clinical trials
Health economics
Incomplete data
Selected Publications
Wileyto E.P, Li Y., Chen J., Heitjan D.F.: Assessing the fit of parametric cure models. Biostatistics 14(2): 340-50, Apr 2013.Sohal D.P., Metz J.M., Sun W., Giantonio B.J., Plastaras J.P., Ginsberg G., Kochman M.L., Teitelbaum U.R., Harlacker K., Heitjan D.F., Feldman M.D., Drebin J.A., O'Dwyer P.J.: Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology Mar, In Press 2013 Notes: Epub ahead of print.
Kang H.C., Tan K.S., Keefe S.M., Heitjan D.F., Siegelman E.S., Flaherty K.T., O'Dwyer P.J., Rosen M.A.: MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. American Journal of Roentgenology 200(1): 120-6, Jan 2013.
Nath K., Nelson D.S., Ho A.M., Lee S.C., Darpolor M.M., Pickup S., Zhou R., Heitjan D.F., Leeper D.B., Glickson J.D.: (31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. NMR in Biomedicine 26(1): 98-105, Jan 2013.
Ying G.S., Heitjan D.F.: Prediction of event times in the REMATCH Trial. Clinical Trials (London, England) 10(2): 197-206, 2013.
St Helen G., Novalen M., Heitjan D.F., Dempsey D., Jacob P. 3rd, Aziziyeh A., Wing V.C., George T.P., Tyndale R.F., Benowitz N.L.: Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiology, Biomarkers, and Prevention 21(7): 1105-14, Jul 2012.
Li, Y., Mick, R., Heitjan, D.F.: A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials. Clinical Trials 2012 Notes: 2012 Apr 20. [Epub ahead of print]
Tizon, R., Frey, N., Heitjan, D.F., Tan, K.S., Goldstein, S.C., Hexner, E.O., Loren, A., Luger, S.M., Reshef, R., Tsai, D., Vogl, D., Davis, J., Vozniak, M., Fuchs, B., Stadtmauer, E.A., Porter, D.L.: High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplantation 2012 Notes: doi:10.1038/bmt.2011.260. [Epub ahead of print]
Santen, R.J., Yue, W., Heitjan, D.F.: Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiology, Biomarkers & Prevention 2012 Notes: doi:10.1158/1055-9965.EPI-12-0043. 2012 May 14 [Epub ahead of print]
Heitjan D.F.: Biology, models, and the analysis of tumor xenograft experiments. Clinical Cancer Research 17(5): 949-51, Mar 2011.